Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Falsified data gets India's largest generic drug-maker into trouble

Nature (2009)Cite this article

US Federal Drug Administration withdraws approval for a score of drugs from Ranbaxy.

Ranbaxy Laboratories — India's biggest drug maker and one of the largest generics firms in the world — has been slapped with tough penalties by the US Food and Drug Administration (FDA) after it was repeatedly caught falsifying data from one of its four Indian manufacturing plants.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Meredith Wadman
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related external links

Ranbaxy

Food and Drug Administration

Generic Pharmaceutical Association

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wadman, M. Falsified data gets India's largest generic drug-maker into trouble. Nature (2009). https://doi.org/10.1038/news.2009.130

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/news.2009.130

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing